shareholders

Contract research, development and manufacturing organization (CRDMO) Anthem Biosciences, which will launch its ₹3,395 crore initial public offering (IPO) next week, is banking on geopolitical tailwinds as global pharma companies …

The unexpected surge in prices for the country’s dominant stock exchange is fuelled by hopes of an imminent listing and attractive valuations, creating huge demand among investors and a significant …